To address questions of whether SGLT2 inhibitors decrease events of SCD, it is necessary to obtain direct evidence of whether SGLT2 inhibitors reduce VAs or not in various patients. The gene discussed is SLC5A2; the disease is Schnyder corneal dystrophy.